FibroGen, Inc. (FGEN) EPS Estimated At $-0.28; Fidus Investment Has 1.4 Sentiment

February 6, 2018 - By Nellie Frank

Analysts expect FibroGen, Inc. (NASDAQ:FGEN) to report $-0.28 EPS on March, 7.They anticipate $0.26 EPS change or 48.15% from last quarter’s $-0.54 EPS. After having $-0.50 EPS previously, FibroGen, Inc.’s analysts see -44.00% EPS growth. The stock decreased 2.26% or $1.2 during the last trading session, reaching $52. About 402,367 shares traded. FibroGen, Inc. (NASDAQ:FGEN) has risen 52.86% since February 6, 2017 and is uptrending. It has outperformed by 36.16% the S&P500.

The stock decreased 2.06% or $0.2795 during the last trading session, reaching $13.2805. About 210,285 shares traded or 80.81% up from the average. Fidus Investment Corporation (FDUS) has risen 12.11% since February 6, 2017 and is uptrending. It has underperformed by 4.59% the S&P500.

FibroGen, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes therapeutic agents to treat serious unmet medical needs in the United States. The company has market cap of $4.26 billion. It is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases that is in Phase III clinical development for the treatment of anemia in chronic kidney disease; Pamrevlumab, a human-monoclonal antibody that inhibits the activity of connective tissue growth factor, which is in Phase II clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, liver fibrosis, and Duchenne muscular dystrophy; and FG-5200 for the treatment of corneal blindness resulting from partial thickness corneal damage. It currently has negative earnings. It has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB.

Among 8 analysts covering FibroGen Inc (NASDAQ:FGEN), 5 have Buy rating, 0 Sell and 3 Hold. Therefore 63% are positive. FibroGen Inc had 16 analyst reports since July 29, 2015 according to SRatingsIntel. On Thursday, January 21 the stock rating was initiated by Credit Suisse with “Neutral”. The firm has “Buy” rating by Stifel Nicolaus given on Sunday, September 10. The stock of FibroGen, Inc. (NASDAQ:FGEN) has “Neutral” rating given on Friday, July 21 by Goldman Sachs. The firm has “Buy” rating given on Wednesday, October 18 by Stifel Nicolaus. As per Wednesday, July 29, the company rating was initiated by Citigroup. The stock of FibroGen, Inc. (NASDAQ:FGEN) earned “Outperform” rating by Credit Suisse on Thursday, February 11. As per Tuesday, August 8, the company rating was maintained by Leerink Swann. The firm earned “Buy” rating on Tuesday, August 8 by Jefferies. The rating was maintained by Jefferies with “Buy” on Monday, August 14. Citigroup initiated the stock with “Buy” rating in Friday, December 4 report.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>